Insulet Free Cash Flow 2010-2024 | PODD
Insulet annual/quarterly free cash flow history and growth rate from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Insulet free cash flow for the quarter ending September 30, 2024 was 211.30, a year-over-year.
- Insulet free cash flow for the twelve months ending September 30, 2024 was , a year-over-year.
- Insulet annual free cash flow for 2023 was $0.07B, a 1897.44% decline from 2022.
- Insulet annual free cash flow for 2022 was $-0.004B, a 97.83% decline from 2021.
- Insulet annual free cash flow for 2021 was $-0.18B, a 300% increase from 2020.
| Insulet Annual Free Cash Flow | |
|---|---|
| 2023 | 70.10 |
| 2022 | -3.90 |
| 2021 | -180.00 |
| 2020 | -45.00 |
| 2019 | -65.30 |
| 2018 | -121.50 |
| 2017 | -32.50 |
| 2016 | -6.20 |
| 2015 | -23.16 |
| 2014 | -2.57 |
| 2013 | -3.96 |
| 2012 | -40.05 |
| 2011 | -36.57 |
| 2010 | -42.17 |
| 2009 | -52.46 |
| Insulet Quarterly Free Cash Flow | |
|---|---|
| 2024-09-30 | 211.30 |
| 2024-06-30 | 139.50 |
| 2024-03-31 | 65.50 |
| 2023-12-31 | 70.10 |
| 2023-09-30 | 54.20 |
| 2023-06-30 | 18.30 |
| 2023-03-31 | -10.00 |
| 2022-12-31 | -3.90 |
| 2022-09-30 | 9.80 |
| 2022-06-30 | -15.80 |
| 2022-03-31 | -26.50 |
| 2021-12-31 | -180.00 |
| 2021-09-30 | -122.70 |
| 2021-06-30 | -69.60 |
| 2021-03-31 | -68.00 |
| 2020-12-31 | -45.00 |
| 2020-09-30 | -11.20 |
| 2020-06-30 | -28.90 |
| 2020-03-31 | -30.50 |
| 2019-12-31 | -65.30 |
| 2019-09-30 | -63.10 |
| 2019-06-30 | -71.50 |
| 2019-03-31 | -37.90 |
| 2018-12-31 | -121.50 |
| 2018-09-30 | -119.40 |
| 2018-06-30 | -98.13 |
| 2018-03-31 | -39.64 |
| 2017-12-31 | -32.50 |
| 2017-09-30 | -28.41 |
| 2017-06-30 | -42.94 |
| 2017-03-31 | -47.51 |
| 2016-12-31 | -6.20 |
| 2016-09-30 | -23.36 |
| 2016-06-30 | -12.74 |
| 2016-03-31 | -13.68 |
| 2015-12-31 | -23.16 |
| 2015-09-30 | -1.08 |
| 2015-06-30 | -7.30 |
| 2015-03-31 | -7.83 |
| 2014-12-31 | -2.57 |
| 2014-09-30 | -4.54 |
| 2014-06-30 | -6.25 |
| 2014-03-31 | -3.17 |
| 2013-12-31 | -3.96 |
| 2013-09-30 | 2.35 |
| 2013-06-30 | 0.48 |
| 2013-03-31 | -2.27 |
| 2012-12-31 | -40.05 |
| 2012-09-30 | -32.40 |
| 2012-06-30 | -24.27 |
| 2012-03-31 | -10.60 |
| 2011-12-31 | -36.57 |
| 2011-09-30 | -26.62 |
| 2011-06-30 | -22.51 |
| 2011-03-31 | -10.76 |
| 2010-12-31 | -42.17 |
| 2010-09-30 | -31.55 |
| 2010-06-30 | -17.04 |
| 2010-03-31 | -10.27 |
| 2009-12-31 | -52.46 |
| 2009-09-30 | -41.43 |
| 2009-06-30 | -29.22 |
| 2009-03-31 | -13.14 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $19.068B | $1.697B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $194.797B | 24.85 |
| Boston Scientific (BSX) | United States | $139.837B | 40.20 |
| Stryker (SYK) | United States | $139.395B | 31.41 |
| EssilorLuxottica (ESLOY) | France | $110.104B | 0.00 |
| Medtronic (MDT) | Ireland | $103.429B | 15.36 |
| Lonza Group Ag (LZAGY) | Switzerland | $43.664B | 0.00 |
| Haleon (HLN) | United Kingdom | $41.193B | 26.76 |
| GE HealthCare Technologies (GEHC) | United States | $38.725B | 20.09 |
| ResMed (RMD) | United States | $34.324B | 28.21 |
| Terumo (TRUMY) | Japan | $28.025B | 39.58 |
| Koninklijke Philips (PHG) | Netherlands | $24.269B | 18.58 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.811B | 13.25 |
| Baxter (BAX) | United States | $15.022B | 9.77 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.471B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.568B | 32.52 |
| BellRing Brands (BRBR) | United States | $9.145B | 36.79 |
| Demant (WILYY) | Denmark | $8.596B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.666B | 15.49 |
| Haemonetics (HAE) | United States | $3.851B | 18.79 |
| ICU Medical (ICUI) | United States | $3.779B | 35.98 |
| Prestige Consumer Healthcare (PBH) | United States | $3.656B | 18.18 |
| Perrigo (PRGO) | Ireland | $3.326B | 9.79 |
| Envista Holdings (NVST) | United States | $3.198B | 23.82 |
| QuidelOrtho (QDEL) | United States | $3.077B | 19.81 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| Neogen (NEOG) | United States | $2.678B | 30.90 |
| GN Store Nord (GNNDY) | Denmark | $2.593B | 16.63 |
| LeMaitre Vascular (LMAT) | United States | $2.104B | 51.14 |
| Green Thumb Industries (GTBIF) | United States | $1.564B | 27.37 |
| AtriCure (ATRC) | United States | $1.531B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.364B | 9.75 |
| InMode (INMD) | Israel | $1.335B | 8.03 |
| BioLife Solutions (BLFS) | United States | $1.234B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.225B | 0.00 |
| Owens & Minor (OMI) | United States | $1.071B | 8.37 |
| Curaleaf Holdings (CURLF) | Canada | $0.942B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.812B | 14.32 |
| CeriBell (CBLL) | United States | $0.750B | 0.00 |
| Evolus (EOLS) | United States | $0.633B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.600B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.551B | 24.31 |
| Surmodics (SRDX) | United States | $0.549B | 0.00 |
| Omeros (OMER) | United States | $0.512B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.459B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.423B | 0.00 |
| ZimVie (ZIMV) | United States | $0.372B | 31.37 |
| Valneva SE (VALN) | France | $0.369B | 0.00 |
| Quanterix (QTRX) | United States | $0.363B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.310B | 29.44 |
| Biote (BTMD) | United States | $0.307B | 6.73 |
| Cerus (CERS) | United States | $0.293B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.282B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.270B | 18.10 |
| Canopy Growth (CGC) | Canada | $0.267B | 0.00 |
| High Tide (HITI) | Canada | $0.250B | 103.00 |
| Zynex (ZYXI) | United States | $0.249B | 52.20 |
| Aurora Cannabis (ACB) | Canada | $0.227B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.224B | 3.15 |
| Utah Medical Products (UTMD) | United States | $0.207B | 14.26 |
| MacroGenics (MGNX) | United States | $0.200B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.198B | 0.00 |
| Brainsway (BWAY) | Israel | $0.177B | 94.00 |
| TerrAscend (TSNDF) | Canada | $0.164B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.157B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.137B | 17.21 |
| Quipt Home Medical (QIPT) | United States | $0.129B | 0.00 |
| Jin Medical (ZJYL) | China | $0.126B | 0.00 |
| Veru (VERU) | United States | $0.114B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.88 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.096B | 0.00 |
| InterCure (INCR) | Israel | $0.076B | 0.00 |
| INLIF (INLF) | $0.068B | 0.00 | |
| Rockwell Medical (RMTI) | United States | $0.067B | 34.67 |
| Apyx Medical (APYX) | United States | $0.060B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.059B | 0.00 |
| Exagen (XGN) | United States | $0.056B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.052B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.051B | 0.00 |
| ImmuCell (ICCC) | United States | $0.046B | 0.00 |
| Modular Medical (MODD) | United States | $0.046B | 0.00 |
| Safety Shot (SHOT) | United States | $0.037B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 13.30 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |